Table 1: Baseline characteristics.
|
|
Stroma-low |
Stroma-high |
|
|
|
N = 138 (%) |
N = 36 (%) |
P-value |
|
Age in years |
|||
|
Median (range) |
65.7 (35.4 - 78.0) |
64.2 (37.5 - 77.2) |
0.27 |
|
Gender |
|||
|
Female |
65 (47.1) |
17 (47.2) |
0.99 |
|
Male |
73 (52.9) |
19 (52.8) |
|
|
Therapy |
|||
|
5-FU/LV |
70 (50.7%) |
18 (50.0%) |
0.94 |
|
Surveillance |
68 (49.3%) |
18 (50.0%) |
|
|
T stage |
|||
|
T3 |
118 (85.5) |
26 (72.2) |
0.06 |
|
T4 |
20 (14.5) |
10 (27.8) |
|
|
Grade |
|||
|
G1 and G2 |
113 (81.9) |
28 (77.8) |
0.58 |
|
G3 and G4 |
25 (18.1) |
8 (22.2) |
|
|
Tumor location |
|||
|
Coecum and right colon |
35 (25.4) |
7 (19.4) |
0.67 |
|
Sigmoid and left colon |
69 (50.0) |
18 (50.0) |
|
|
Flexures and transverse colon |
34 (24.6) |
11 (30.6) |
TSR: Tumor-Stroma Ratio; 5-FU: 5-Fluorouracil; LV: leucovorin.